



**IBC Meeting Minutes**  
**Date: November 19, 2025**  
**Location: Conf. Room 2101/2102**

**Voting Members Present (10):**

Michael Henderson, Ph.D. (Chair)  
Glen Alberts, B.S.  
Pamela Bartlett, B.S.  
Scott Bechaz, ILAM, RLATg  
Craig Bickel, M.Div.  
Nicholas Burton, Ph.D.  
Matthew Donahue, MBA  
Angie Jason (non-voting)  
Lauren Miedema, B.S., MPH  
Rachael Sheridan, Ph.D.  
Jennifer Steiner, Ph.D.

**Voting Members Excused (1):**

Sam Pinto, B.S. (Vice Chair)

Christy Goss (guest)

Call to Order

Michael Henderson, Chair called the meeting to order at 9:33 a.m.

Meeting Minutes – Minutes from the IBC meeting on 10/15/25 were approved unanimously.

Vote: (9 Total)      9 Approve    0 Disapprove    0 Abstain    0 Recuse

*Matthew Donahue joined the meeting*

New Business –

- SOP – “Alpha-bungarotoxin” – Glen Alberts reviewed this new SOP.  
Vote: (10 Total)      10 Approve    0 Disapprove    0 Abstain    0 Recuse
- SOP – “Handling and Use of *S. Typhimurium* in Zebrafish Experimental Models” – Glen Alberts reviewed this new SOP.  
Vote: (10 Total)      10 Approve    0 Disapprove    0 Abstain    0 Recuse

Protocol Reviews

**A. Reference #25-0106 – Initial – Margarita Parada-Kusz, Ph.D.**

*“Use of Salmonella enterica Serovar Typhimurium in Zebrafish Larvae to Study Host-Pathogen interactions”*

Primary Reviewer: Glen Alberts

The purpose of this protocol is to examine how early life systemic infections with *Salmonella enterica* can become systemic, affect brain development and whether they increase susceptibility to neurodegeneration later in life. The members determined that the proposed study procedures, practices and the training and expertise of the personnel who will be conducting the study are appropriate, but do not require an IBC protocol based on the *NIH Guidelines*; however, the following clarifications must be provided.

1. General Information - The investigator was asked to attach an SOP for alpha-bungarotoxin and place this toxin name on the signage.

Risk Group: 2

Containment Level: BSL2

Location Assessment: Phase 1 Level 4 (Parada-Kusz laboratory) Bay 3

Action: Approved as SOP; IBC protocol not required

Vote: (10 Total)      10 Approve      0 Disapprove      0 Abstain      0 Recuse

**B. Reference #25-0102 – 3 Year Re-Write – Laurent Roybon, Ph.D.**

*“Generation of iPSC from patient somatic cells including post-mortem tissue”*

Primary Reviewer: Jennifer Steiner

The purpose of this protocol is to study early brain cell dysfunctions that lead to disease. By comparing cells from early and late stages of disease, researchers can uncover how brain injury develops, paving the way for earlier diagnosis, personalized treatments, and prevention strategies. The members determined that the proposed study procedures, practices and the training and expertise of the personnel who will be conducting the study are appropriate, but the following clarifications must be provided.

1. General Information - The investigator was asked to update the room numbers in attached SOP.
2. rDNA. The investigator was asked to attach the Human Materials Safety SOP.

Applicable section of the *NIH Guidelines* the research falls under: Section III-D-1.

Risk Group: 2

Containment Level: BSL2

Location Assessment: Room 2108, floor 2

Action: Modifications to secure approval.

Vote: (10 Total)      10 Approve      0 Disapprove      0 Abstain      0 Recuse

Meeting was adjourned at 10:00 am